X

Drug Profile

EB 003

Alternative Names: EB-003

Latest Information Update: 14 Nov 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eligo Bioscience
Class Bacteriophages; Gene therapies
Mechanism of Action Bacterial DNA inhibitors; Cell death stimulants; Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Diarrhoea
New Molecular Entity No

Highest Development Phases

Preclinical Diarrhoea

Most Recent Events

11 Oct 2022 EB 003 receives Orphan Drug status for Diarrhoea in USA
11 Oct 2022 EB 003 receives rare paediatric disease designation for Diarrhoea in USA
03 Oct 2022 Eligo Bioscience has patent protection for microbiome gene editing therapy in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com